Literature DB >> 33554567

An original multiplex method to assess five different SARS-CoV-2 antibodies.

Julien Favresse1,2, Jonathan Brauner3, Nicolas Bodart4, Alain Vigneron4, Sandrine Roisin3, Sabrina Melchionda5, Jonathan Douxfils2,5, Annick Ocmant3.   

Abstract

OBJECTIVES: Accurate SARS-CoV-2 serological assays are urgently needed to help diagnose infection, determine past exposure of populations and assess the response to future vaccines. The study aims at assessing the performance of the multiplex D-tek COVIDOT 5 IgG assay for the detection of SARS-CoV-2 IgG antibodies (N, S1+S2, S1, S2 and RBD).
METHODS: Sensitivity and dynamic trend to seropositivity were evaluated in 218 samples obtained from 46 rRT-PCR confirmed COVID-19 patients. Non-SARS-CoV-2 sera (n=118) collected before the COVID-19 pandemic with a potential cross-reaction to the SARS-CoV-2 immunoassay were included in the specificity analysis.
RESULTS: A gradual dynamic trend since symptom onset was observed for all IgG antibodies. Sensitivities before day 14 were suboptimal. At ≥21 days, sensitivities reached 100% (93.4-100%) for N, S1+S2, S2 and RBD-directed IgG and 96.3% (87.3-99.6%) for S1-directed IgG. In 42 out of 46 patients (91.3%), all five antibodies were detected at ≥14 days. The four remaining patients had between 2 and 4 positive antibodies at their respective maximal follow-up period. The specificity was 100 % for S1+S2, S2 and RBD, 98.3% for N and 92.4% (86.0-96.5%) for S1-directed IgG. The combined use of antigens increases the early sensitivity whilst enforcing high specificity.
CONCLUSIONS: Sensitivities at ≥21 days and specificities were excellent, especially for N, S1+S2, S2 and RBD-directed IgG. Caution is however required when interpreting single S1-directed reactivities. Using a multiplex assay complies with the orthogonal testing algorithm of the CDC and allows a better and critical interpretation of the serological status of a patient.
© 2020 Walter de Gruyter GmbH, Berlin/Boston.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; kinetics; multiplex; serology

Year:  2020        PMID: 33554567     DOI: 10.1515/cclm-2020-1652

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  5 in total

Review 1.  Review of COVID-19 testing and diagnostic methods.

Authors:  Olena Filchakova; Dina Dossym; Aisha Ilyas; Tamila Kuanysheva; Altynay Abdizhamil; Rostislav Bukasov
Journal:  Talanta       Date:  2022-03-31       Impact factor: 6.556

2.  Microarray-Based Detection of Antibodies against SARS-CoV-2 Proteins, Common Respiratory Viruses and Type I Interferons.

Authors:  Elena Savvateeva; Marina Filippova; Vladimir Valuev-Elliston; Nurana Nuralieva; Marina Yukina; Ekaterina Troshina; Vladimir Baklaushev; Alexander Ivanov; Dmitry Gryadunov
Journal:  Viruses       Date:  2021-12-20       Impact factor: 5.048

3.  Performance of SARS-CoV-2 Antigens in a Multiplex Bead Assay for Integrated Serological Surveillance of Neglected Tropical and Other Diseases.

Authors:  Sarah Gwyn; Ado Abubakar; Oluwaseun Akinmulero; Eric Bergeron; Ugboaja Nkechi Blessing; Jasmine Chaitram; Melissa M Coughlin; Ayuba B Dawurung; Felicia Nwatu Dickson; Mudiaga Esiekpe; Erasogie Evbuomwan; Stacie M Greby; Nnaemeka C Iriemenam; Markus H Kainulainen; Thomas Andrew Naanpoen; Loveth Napoloen; Ifeanyichukwu Odoh; McPaul Okoye; Temitope Olaleye; Amy J Schuh; S Michele Owen; Awala Samuel; Diana L Martin
Journal:  Am J Trop Med Hyg       Date:  2022-06-27       Impact factor: 3.707

4.  Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection.

Authors:  Julien Favresse; Christine Eucher; Marc Elsen; Constant Gillot; Sandrine Van Eeckhoudt; Jean-Michel Dogné; Jonathan Douxfils
Journal:  Microorganisms       Date:  2021-03-08

5.  Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2.

Authors:  Julien Favresse; Constant Gillot; Laura Di Chiaro; Christine Eucher; Marc Elsen; Sandrine Van Eeckhoudt; Clara David; Laure Morimont; Jean-Michel Dogné; Jonathan Douxfils
Journal:  Viruses       Date:  2021-07-14       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.